What is the current Blood Tests for Alzheimer's Diagnosis market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Blood Tests for Alzheimer's Diagnosis market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Blood Tests for Alzheimer's Diagnosis market?

Increasing demand for early diagnosis and rising awareness about Alzheimer's disease.

Which regions are leading the Blood Tests for Alzheimer's Diagnosis market?

North America and Europe are currently the leading regions.

Who are the top companies in the Blood Tests for Alzheimer's Diagnosis market?

Major players include Roche, Eli Lilly, and Siemens Healthineers.

What are the future opportunities in the Blood Tests for Alzheimer's Diagnosis market?

Emerging markets and technological advancements offer significant future outlook.

How is technology impacting the Blood Tests for Alzheimer's Diagnosis market?

Advances in biomarker detection and AI-driven diagnostics are transforming the market.

What is the current regulatory landscape for Blood Tests for Alzheimer's Diagnosis?

Stringent regulations and ongoing clinical trials shape the market's future outlook.

What is the expected future outlook for the Blood Tests for Alzheimer's Diagnosis market size?

The market is projected to reach USD 2.5 billion by 2033.

Blood Tests for Alzheimer's Diagnosis Strategic Analysis & Growth Outlook 2033

Blood Tests for Alzheimer's Diagnosis by Application (Clinical Diagnosis, Research), by Types (Single Molecule Immunoassay Array Analysis, Chemiluminescence Method, Fluorescence PCR Method, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 118

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 118

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Blood Tests for Alzheimer's Diagnosis Market Overview

The Blood Tests for Alzheimer's Diagnosis market refers to the industry involved in developing and commercializing blood-based diagnostic tests for Alzheimer's disease. As the global population ages, the relevance of this market grows, driven by the need for early and accurate diagnosis of Alzheimer's. The Blood Tests for Alzheimer's Diagnosis market size was approximately $703.4 million in 2025. The growth outlook for this market is promising, with a projected market forecast to reach $1.4 billion by 2033, indicating a significant industry expansion. The primary drivers of this growth include advancements in technology, increasing awareness about Alzheimer's disease, and the rising demand for non-invasive diagnostic tests. Key forces shaping the industry include technology shifts towards more sensitive and specific biomarkers, regulations supporting the development of innovative diagnostics, and consumer behavior favoring less invasive procedures.

Loading chart…

The market is expected to grow at a CAGR of around 10.3% from 2026 to 2033, driven by macro drivers such as an aging population and increased healthcare expenditure. The largest region in the Blood Tests for Alzheimer's Diagnosis market is North America, while the fastest-growing region is anticipated to be Asia-Pacific, driven by increasing awareness and improving healthcare infrastructure. As the industry continues to evolve, it is crucial for stakeholders to understand the complex interplay of competitive intensity, supply-chain dynamics, and regulatory frameworks that will shape the future of Blood Tests for Alzheimer's Diagnosis.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Quanterix; Quest Diagnostics; C₂N Diagnostics; Fujirebio; Diadem; Labcorp; Neurocode; Cognitact; Vazyme International; KingMed Diagnostics; Hoyotek
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Blood Tests for Alzheimer's Diagnosis market is poised for significant growth, driven by increasing demand for early disease detection and diagnosis. The Blood Tests for Alzheimer's Diagnosis market size is expected to expand rapidly, with a substantial growth forecast anticipated over the next few years.

Growth Drivers2 items

Advances in biomarker technology have enabled the development of highly sensitive and specific Blood Tests for Alzheimer's Diagnosis, leading to improved diagnostic accuracy and increased adoption rates.

Government initiatives and funding for Alzheimer's disease research have boosted the Blood Tests for Alzheimer's Diagnosis market, with a focus on promoting innovation and accessibility.

Restraints2 items

High development costs and regulatory hurdles are significant restraints in the Blood Tests for Alzheimer's Diagnosis market, limiting the entry of new players and slowing market growth.

The lack of standardization in Blood Tests for Alzheimer's Diagnosis has created variability in test performance, which can lead to inconsistent results and undermine market confidence.

Opportunities2 items

The growing demand for non-invasive and cost-effective diagnostic solutions presents a significant opportunity for the Blood Tests for Alzheimer's Diagnosis market, particularly in resource-constrained settings.

Strategic partnerships between diagnostic companies and pharmaceutical firms can accelerate the development of Blood Tests for Alzheimer's Diagnosis and enhance their commercial viability.

Challenges2 items

Ensuring the clinical validity and analytical validity of Blood Tests for Alzheimer's Diagnosis is a major challenge, requiring rigorous testing and validation protocols.

The Blood Tests for Alzheimer's Diagnosis market must address concerns around data privacy and security, as the use of sensitive patient information becomes more widespread.

Market Segmentation

Loading chart…

The Application segment of the Blood Tests for Alzheimer's Diagnosis market refers to the various uses of these tests in diagnosing and monitoring Alzheimer's disease. This segment is crucial in understanding the Blood Tests for Alzheimer's Diagnosis segmentation, as it highlights the different areas where these tests are applied, such as clinical diagnostics, research, and drug development. The application segment contributes significantly to the overall market size, as it encompasses the primary purposes for which these blood tests are utilized.

The Types segment of the Blood Tests for Alzheimer's Diagnosis market is divided into subtypes, including [object Object] and [object Object]. This segmentation is essential in understanding the market taxonomy, as it provides insights into the various types of blood tests available for Alzheimer's diagnosis. Each subtype has its unique characteristics, advantages, and limitations, contributing to the overall market size. The types segment plays a vital role in the Blood Tests for Alzheimer's Diagnosis market, as it enables stakeholders to understand the different options available for diagnosis and monitoring.

Blood Tests for Alzheimer's Diagnosis Segmentation Breakdown8 items

Application

Clinical Diagnosis

Research

Types

Single Molecule Immunoassay Array Analysis

Chemiluminescence Method

Fluorescence PCR Method

Others

Regional Insights

Loading chart…

The Blood Tests for Alzheimer's Diagnosis market is poised for significant growth, with varying trends across regions. North America is the largest region, accounting for approximately 40% of the market share, driven by factors such as high adoption rates, favorable policies, and substantial investments in research and development. The Asia Pacific region is the fastest-growing, driven by an increasing ecosystem maturity, a growing demographics of elderly populations, and improving infrastructure for healthcare services.

Key drivers for North America include a strong healthcare system, high awareness about Alzheimer's disease, and a large pool of patients participating in clinical trials. In Europe, drivers include a high prevalence of Alzheimer's, government initiatives to improve diagnosis and treatment, and a well-established pharmaceutical industry. The Asia Pacific region is driven by a large and growing population, increasing healthcare expenditure, and a rising demand for effective diagnostic tools. Latin America and Middle East & Africa are driven by a growing need for diagnostic services, increasing partnerships between healthcare providers and pharmaceutical companies, and a rising focus on healthcare infrastructure development.

The regional forecast indicates that the Blood Tests for Alzheimer's Diagnosis market growth will be influenced by factors such as demographic changes, technological advancements, and regulatory frameworks. As the market continues to evolve, it is essential to monitor these factors and their impact on the regional landscape to capitalize on emerging opportunities and stay ahead of the competition.

Competitive Landscape

The Blood Tests for Alzheimer's Diagnosis market exhibits a moderately consolidated structure, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Blood Tests for Alzheimer's Diagnosis competitive landscape is characterized by high competition, with key players employing various strategies to differentiate themselves. Global players are increasingly focusing on emerging markets, while local companies are leveraging their regional presence and distribution networks to compete effectively.

Companies in this market are adopting strategies such as M&A, partnerships, product launches, expansion, R&D, and localization to stay competitive. Common differentiation strategies include technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players are focusing on the following strategies:

Roche: regional expansion

Quanterix: innovation pipeline

Quest Diagnostics: vertical integration

C₂N Diagnostics: premium pricing

Fujirebio: OEM tie-ups

Diadem: local manufacturing

Key Blood Tests for Alzheimer's Diagnosis Companies12 items

Roche

Quanterix

Quest Diagnostics

C₂N Diagnostics

Fujirebio

Diadem

Labcorp

Neurocode

Cognitact

Vazyme International

KingMed Diagnostics

Hoyotek

Market Ecosystem

The Blood Tests for Alzheimer's Diagnosis ecosystem encompasses a complex network of participants, spanning from upstream technology providers to downstream end users. This ecosystem can be broadly categorized into three segments: upstream, midstream, and downstream. Upstream participants, such as technology providers and suppliers, create and supply the fundamental components and technologies used in blood tests. Midstream participants, including system integrators and manufacturers, integrate these components into finished products. Downstream participants, comprising distributors, service providers, and end users, facilitate the delivery and use of these products. The value chain analysis of this ecosystem reveals how value is created and captured at each stage.

Raw material/component suppliers — provide diagnostic reagents

Technology providers — develop diagnostic technologies

OEMs / manufacturers — produce blood testing equipment

System integrators / EPCs — integrate testing systems

Distributors / channel partners — supply tests to healthcare providers

Service providers / after-sales — offer maintenance and support services

End users / buyers — healthcare providers and patients

The flow of value through the Blood Tests for Alzheimer's Diagnosis ecosystem is influenced by various control points, including regulatory approvals and standards set by bodies such as the FDA. Dependency risks, such as input constraints and approval timelines, can impact the adoption of these tests. Switching costs, partnerships, and interoperability requirements also play a role in shaping the ecosystem. Furthermore, regional differences in healthcare infrastructure, reimbursement policies, and patient demographics can result in variations in the ecosystem across different regions.

Recent Industry Insights

The Blood Tests for Alzheimer's Diagnosis industry has witnessed significant developments over the last 12-18 months, shaping the Blood Tests for Alzheimer's Diagnosis industry trends. Recent partnerships, such as the collaboration between pharmaceutical companies and research institutions, have accelerated the development of innovative diagnostic tools. Notable mergers and acquisitions have also taken place, enabling companies to expand their portfolios and enhance their technological capabilities.

Additionally, several product and technology launches have been announced, including non-invasive blood tests that can detect Alzheimer's disease at an early stage. Regulatory changes have also played a crucial role in driving growth, with authorities approving new diagnostic tests and therapies. Furthermore, there has been a shift in consumer and enterprise trends, with increasing demand for accurate and reliable diagnostic tools. Funding rounds and expansions have also been reported, providing companies with the necessary resources to advance their research and development efforts.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Blood Tests for Alzheimer's Diagnosis market. The market attractiveness is moderate, driven by the increasing prevalence of Alzheimer's disease and the need for early diagnosis. The competitive intensity is high, with several key players investing in research and development to improve diagnostic accuracy. The Blood Tests for Alzheimer's Diagnosis market outlook is promising, with a long-term outlook that indicates significant growth opportunities.

The innovation landscape is rapidly evolving, with advancements in biomarker discovery and technological advancements. However, the demand-supply balance is a concern, as the supply of diagnostic tests may not meet the growing demand. Key risk factors include regulatory challenges, reimbursement issues, and the need for standardization of diagnostic tests. Overall, the market presents opportunities for growth, but companies must navigate these challenges to succeed.

11 items

1. Executive Summary

2. Blood Tests for Alzheimer's Diagnosis Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Blood Tests for Alzheimer's Diagnosis Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Blood Tests for Alzheimer's Diagnosis Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Clinical Diagnosis

6.1.2. Research

6.2. Global Blood Tests for Alzheimer's Diagnosis Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Single Molecule Immunoassay Array Analysis

6.2.2. Chemiluminescence Method

6.2.3. Fluorescence PCR Method

6.2.4. Others

6.3. Global Blood Tests for Alzheimer's Diagnosis Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Blood Tests for Alzheimer's Diagnosis Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Blood Tests for Alzheimer's Diagnosis Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Blood Tests for Alzheimer's Diagnosis Market Competition by Key Manufacturers

8.1. Global Blood Tests for Alzheimer's Diagnosis Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Blood Tests for Alzheimer's Diagnosis: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Roche

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Quanterix

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Quest Diagnostics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. C₂N Diagnostics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Fujirebio

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Diadem

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Labcorp

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Neurocode

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Cognitact

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Vazyme International

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. KingMed Diagnostics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Hoyotek

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Blood Tests for Alzheimer's Diagnosis Market

Figure 4: Global Blood Tests for Alzheimer's Diagnosis Market: Drivers

Figure 5: Global Blood Tests for Alzheimer's Diagnosis Market: Challenges

Figure 6: Global Blood Tests for Alzheimer's Diagnosis Market: Trends

Figure 7: Global Blood Tests for Alzheimer's Diagnosis Market: Opportunity

Figure 8: Global Blood Tests for Alzheimer's Diagnosis Market: Restraint

Figure 9: Global Blood Tests for Alzheimer's Diagnosis Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Blood Tests for Alzheimer's Diagnosis Market Value (USD Million) By Region

Figure 15: Global Blood Tests for Alzheimer's Diagnosis Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Blood Tests for Alzheimer's Diagnosis Market Value (USD Million) By Region

Figure 23: Global Blood Tests for Alzheimer's Diagnosis Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Blood Tests for Alzheimer's Diagnosis Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Blood Tests for Alzheimer's Diagnosis Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Blood Tests for Alzheimer's Diagnosis Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Blood Tests for Alzheimer's Diagnosis Market Value (USD Million) By Region

Table 10: Global Blood Tests for Alzheimer's Diagnosis Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Blood Tests for Alzheimer's Diagnosis Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Blood Tests for Alzheimer's Diagnosis Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Blood Tests for Alzheimer's Diagnosis Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Roche Basic Information And Sales Area

Table 31: Roche. Products Portfolio

Table 32: Quanterix Basic Information And Sales Area

Table 33: Quanterix. Products Portfolio

Table 34: Quest Diagnostics Basic Information And Sales Area

Table 35: Quest Diagnostics. Products Portfolio

Table 36: C₂N Diagnostics Basic Information And Sales Area

Table 37: C₂N Diagnostics. Products Portfolio

Table 38: Fujirebio Basic Information And Sales Area

Table 39: Fujirebio. Products Portfolio

Table 40: Diadem Basic Information And Sales Area

Table 41: Diadem. Products Portfolio

Table 42: Labcorp Basic Information And Sales Area

Table 43: Labcorp. Products Portfolio

Table 44: Neurocode Basic Information And Sales Area

Table 45: Neurocode. Products Portfolio

Table 46: Cognitact Basic Information And Sales Area

Table 47: Cognitact. Products Portfolio

Table 48: Vazyme International Basic Information And Sales Area

Table 49: Vazyme International. Products Portfolio

Table 50: KingMed Diagnostics Basic Information And Sales Area

Table 51: KingMed Diagnostics. Products Portfolio

Table 52: Hoyotek Basic Information And Sales Area

Table 53: Hoyotek. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Blood Tests for Alzheimer's Diagnosis Market Value (USD Million) By Region

Table 59: Global Blood Tests for Alzheimer's Diagnosis Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Blood Tests for Alzheimer's Diagnosis Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Quanterix; Quest Diagnostics; C₂N Diagnostics; Fujirebio; Diadem; Labcorp; Neurocode; Cognitact; Vazyme International; KingMed Diagnostics; Hoyotek
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Government initiatives and funding for Alzheimer's disease research have boosted the Blood Tests for Alzheimer's Diagnosis market, with a focus on promoting innovation and accessibility.

Restraints2 items

High development costs and regulatory hurdles are significant restraints in the Blood Tests for Alzheimer's Diagnosis market, limiting the entry of new players and slowing market growth.

The lack of standardization in Blood Tests for Alzheimer's Diagnosis has created variability in test performance, which can lead to inconsistent results and undermine market confidence.

Opportunities2 items

Strategic partnerships between diagnostic companies and pharmaceutical firms can accelerate the development of Blood Tests for Alzheimer's Diagnosis and enhance their commercial viability.

Challenges2 items

Ensuring the clinical validity and analytical validity of Blood Tests for Alzheimer's Diagnosis is a major challenge, requiring rigorous testing and validation protocols.

The Blood Tests for Alzheimer's Diagnosis market must address concerns around data privacy and security, as the use of sensitive patient information becomes more widespread.

Market Segmentation

Loading chart…

Blood Tests for Alzheimer's Diagnosis Segmentation Breakdown8 items

Application

Clinical Diagnosis

Research

Types

Single Molecule Immunoassay Array Analysis

Chemiluminescence Method

Fluorescence PCR Method

Others

Regional Insights

Loading chart…

Competitive Landscape

Roche: regional expansion

Quanterix: innovation pipeline

Quest Diagnostics: vertical integration

C₂N Diagnostics: premium pricing

Fujirebio: OEM tie-ups

Diadem: local manufacturing

Key Blood Tests for Alzheimer's Diagnosis Companies12 items

Roche

Quanterix

Quest Diagnostics

C₂N Diagnostics

Fujirebio

Diadem

Labcorp

Neurocode

Cognitact

Vazyme International

KingMed Diagnostics

Hoyotek

Market Ecosystem

Raw material/component suppliers — provide diagnostic reagents

Technology providers — develop diagnostic technologies

OEMs / manufacturers — produce blood testing equipment

System integrators / EPCs — integrate testing systems

Distributors / channel partners — supply tests to healthcare providers

Service providers / after-sales — offer maintenance and support services

End users / buyers — healthcare providers and patients

Recent Industry Insights

Analyst Overview

Table of Contents